版本:
中国

BRIEF-Vivus and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra

Oct 3 VIVUS Inc :

* VIVUS Inc says additionally, Metuchen will be responsible for royalties due to Mitsubishi Tanabe Pharma corporation based on net sales

* VIVUS and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra

* VIVUS-Signed commercial supply agreement pursuant to which Co to be responsible for manufacture, supply of Stendra to Metuchen; VIVUS received $70 million Source text for Eikon: Further company coverage: ;))

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐